This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): rotigotine TDS, rotigotine CDS, SPM 962, SPM-962, SPM 936, Leganto (EU), transdermal rotigotine
US historical revenues for Neupro represent total North America sales.
Neupro is a transdermal, continuous delivery system containing rotigotine, a dopamine agonist (ie, it stimulates the dopamine receptor).
Deal Structure: In 1998, Aderis licensed worldwide development and commercialization rights for Rotigotine TDS to Schwarz Pharma.
In November 2002, Schwarz licensed the Japanese development and marketing rights for Neupro to Otsuka Pharmaceutical. Under the agreement, Schwarz Pharma receives milestone payments from Otsuka.
In July 2005, Schwarz acquired all remaining rights to the rotigotine compound from Aderis.
In July 2007, UCB acquired Schwarz Pharma.
In November 2012, UCB and NewBridge announced an exclusive partnership agreement to make UCBs core products Cimzia, Vimpat, and Neupro available in several Middle East and African countries. Under the agreement, NewBridge acquires the rights to Cimzia, Vimpat, and Neupro from the RX Group, UCBs previous partner in the region. UCB will now operate with its new partner for the region and will supply NewBridge with the three products on exclusive basis. NewBridge will also be responsible for managing the local regulatory approval...See full deal structure in Biomedtracker
Partners: Otsuka Holdings Co., Ltd. NewBridge Pharmaceuticals
Pink Sheet Neupro FDA Reviewers
Pink Sheet Neupro Clinical Development
Additional information available to subscribers only: